COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,436 Articles (22,835 medRxiv, 8,601 bioRxiv)

Most recent first Previous |  Page 769: Articles 7681-7690  | Next

Forecasting hospital-level COVID-19 admissions using real-time mobility data
Klein, B., Zenteno, A. C., Joseph, D., Zahedi, M., Hu, M., Copenhaver, M., Kraemer, M. U. G., Chinazzi, M., Klompas, M., Vespignani, A., Scarpino, S. V., Salmasian, H.
10.1101/2022.06.06.22275840 — Posted: 2022-06-08
COVID-19 and per capita green tea consumption: update
Storozhuk, M.
10.1101/2022.06.06.22276060 — Posted: 2022-06-07
Evolution of long-term hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study
Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva Reyes, L., Meardon, N., Faustini, S., Al-Taei, S., Tipton, T., Hering, L. M., Angyal, A., Brown, R., Nicols, A. R., Dobson, S. L., Supasa, P., Tuekprakhon, A., Cross, A., Tyerman, J. K., Hornsby, H., Grouneva, I., Plowright, M., Zhang, P., Newman, T. A. H., Nell, J. M., Abraham, P., Ali, M., Malone, T., Neale, I., Phillips, E., Wilson, J. D., Shields, A., Horner, E. C., Booth, L. H., Stafford, L., Bibi, S., Wootton, D. G., Mentzer, A. J., Conlon, C. P., Jeffery, K., Matthews, P. C., Pollard, A
10.1101/2022.06.06.22275865 — Posted: 2022-06-07
Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro
Zhou, Y., Gammeltoft, K. A., Ryberg, L. A., Pham, L. V., Fahnoe, U., Binderup, A., Hernandez, C. R. D., Offersgaard, A., Fernandez-Antunez, C., Peters, G. H. J., Ramirez, S., Bukh, J., Gottwein, J. M.
10.1101/2022.06.06.494921 — Posted: 2022-06-07
The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir
Jochmans, D., Liu, C., Donckers, K., Stoycheva, A., Boland, S., Stevens, S. K., De Vita, C., Vanmechelen, B., Maes, P., Trüeb, B. S., Ebert, N., Thiel, V., De Jonghe, S., Vangeel, L., Bardiot, D., Jekle, A., Blatt, L. M., Beigelman, L., Symons, J. A., Raboisson, P., Chaltin, P., Marchand, A., Neyts, J., Deval, J., Vandyck, K.
10.1101/2022.06.07.495116 — Posted: 2022-06-07
Development of an Escape-resistant SARS CoV-2 Neutralizing Synthetic Nanobody
Dormeshkin, D., Shapira, M., Dubovik, S., Kavaleuski, A., Katsin, M., Migas, A., Meleshko, A., Semyonov, S.
10.1101/2022.06.07.495065 — Posted: 2022-06-07
Within-host diversity improves phylogenetic and transmission reconstruction of SARS-CoV-2 outbreaks
Ortiz, A. T., Kendall, M., Storey, N., Hatcher, J., Dunn, H., Roy, S., Williams, R., Williams, C., Goldstein, R. A., Didelot, X., Harris, K., Breuer, J., Grandjean, L.
10.1101/2022.06.07.495142 — Posted: 2022-06-07
GABA-receptors are a new druggable target for limiting disease severity, lung viral load, and death in SARS-CoV-2 infected mice
Tian, J., Dillion, B., Henley, J., Comai, L., Kaufman, D.
10.1101/2022.06.07.494579 — Posted: 2022-06-07
Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform
Fisher, C. R., Medie, F. M., Luu, R. J., Quezada, L. L., Gaibler, R. B., Mulhern, T. J., Rubio, L. D., Marr, E. E., Gabriel, E. P., Borenstein, J. T., Gard, A. L.
10.1101/2022.06.07.495101 — Posted: 2022-06-07
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection
Kurhade, C., Zou, j., Xia, H., Liu, M., Yang, Q., Cutler, M., Cooper, D., Muik, A., Sahin, U., Jansen, K. U., Ren, P., Xie, X., Shi, P.-Y.
10.1101/2022.06.05.494889 — Posted: 2022-06-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).